Oncolytics Biotech (TSE:ONC) Trading 2.9% Higher – Still a Buy?

Shares of Oncolytics Biotech Inc. (TSE:ONC) shot up 2.9% during mid-day trading on Thursday . The company traded as high as C$1.08 and last traded at C$1.05. 258,089 shares traded hands during trading, an increase of 79% from the average session volume of 144,119 shares. The stock had previously closed at C$1.02.

Analyst Ratings Changes

Separately, Raymond James upgraded Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Performance

The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The company has a fifty day moving average price of C$1.23 and a 200 day moving average price of C$1.36. The stock has a market cap of C$88.39 million, a PE ratio of -3.03 and a beta of 1.35.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same quarter in the previous year, the company posted ($0.14) earnings per share. Analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.